Reproductive Medicine Developer Nora Therapeutics Raises $18M
April 18, 2014
Development of reproductive medicine got a boost with the $18 million Series B funding of Nora Therapeutics. The round was led by Novo A/S and included participation from Burrill & Company, Prospect Venture Partners, Rho Venture and Vivo Ventures. The money will help Nora further develop its lead drug, NT 100, which is designed to increase the success rates and outcomes for women who have undergone multiple, unsuccessful in vitro fertilization procedures.